| Popis: |
Bone tumors are very rare. They account for about 0.8% of all human neoplasms. Molecular techniques have a quite limited application in this field, because few entities show characteristic aberrations useful for diagnostic and therapeutical purposes. The prototype of these entities is the Ewing sarcoma, typically recognized by recurrent translocations. Often are described new aberrations, such as point mutations or gene amplifications that can occur in bone tumors. The major problem in this very specialized field is the kind of tissue, the bone, that needs decalcification, and this treatment can interfere with nucleic acid isolation. In the decalcified tissues, the affordability of molecular techniques is low (reported to be around 20%). For this reason, it is important to sample bone tumors before the decalcification process in order to store adequate tissue in biobanks for molecular purposes. A valid alternative choice could be to use adequate systems of decalcification that sufficiently preserve the quality of nucleic acids. |
